更新于:2024-11-21

GRO beta

概要

基本信息

药物类型
合成多肽
别名
GROß、GroβT
+ [4]
靶点
作用机制
CXCR2激动剂(C-X-C基序趋化因子受体2激动剂)
治疗领域
在研适应症
非在研机构
最高研发阶段临床1期
首次获批日期-
最高研发阶段(中国)-
特殊审评-
登录后查看时间轴

研发状态

10 条进展最快的记录,
登录
后查看更多信息
适应症最高研发状态国家/地区公司日期
骨髓增生异常综合征申请上市
美国
Ensoma, Inc.Ensoma, Inc.初创企业
2021-06-16
造血干细胞移植临床1期--
镰状细胞血症临床前
美国
Ensoma, Inc.Ensoma, Inc.初创企业
2022-06-24
急性淋巴细胞白血病临床前
美国
Ensoma, Inc.Ensoma, Inc.初创企业
2021-06-16
急性髓性白血病临床前
美国
Ensoma, Inc.Ensoma, Inc.初创企业
2021-06-16
多发性骨髓瘤药物发现
美国
2020-10-05
干细胞动员药物发现
美国
2020-09-14
登录后查看更多信息

临床结果

适应症
分期
评价
查看全部结果
研究
分期
人群特征评价人数分组结果评价发布日期
临床2期
7
獵鬱壓齋製簾醖襯築淵(襯夢鑰憲鏇鑰鏇糧衊膚) = 鹽繭襯鹹鬱範糧廠願衊 壓獵積遞簾壓夢襯壓鹹 (獵選蓋願獵蓋願製願鏇, 蓋觸鑰獵鹽齋網淵積淵 ~ 鑰糧鑰齋艱壓蓋繭選艱)
-
2024-08-29
临床2期
25
夢襯鹽窪願壓鏇製觸願(夢蓋蓋糧蓋壓淵衊願膚) = 膚鹹廠築構觸觸壓鹹獵 構範淵糧願壓遞構構鏇 (醖壓衊艱鏇願鹽積遞艱, 憲鑰鹹觸鹽醖憲淵鬱醖 ~ 蓋鑰範齋衊選鏇糧鏇鬱)
-
2022-09-10
临床2期
25
淵觸願範築繭鹽網艱鏇(選鬱憲遞夢膚網齋繭壓) = At least 1 treatment emergent AE (TEAE) with MGTA-145 was seen in 60% of patients (grade 1, n= 14, grade 2, n=1). Pain (all grade 1) was most common, seen in 44% (11), with 38% (9) patients experiencing acute onset transient bone pain with MGTA-145 (duration: 7 minutes, range: 3-28) 構鑰觸鹹顧網襯襯觸選 (選齋選鹹衊觸廠構願構 )
积极
2022-03-01
临床2期
25
(積淵範衊齋簾網衊觸獵) = At least 1 adverse event (AE) was seen in 90% of patients, 20% had grade 2 AEs (anemia, hypokalemia) and 20% had grade 3 AEs (worsening of baseline grade 3 anemia; hypocalcemia); all resolved. Acute & transient bone pain was seen in 40% of patients (back-2, hip-1, sternum-1), all grade 1, all on day 1, & resolved without intervention after 6 minutes (3-10) 鬱淵積醖衊鏇願製憲窪 (窪築壓顧構齋鏇選窪獵 )
积极
2021-05-28
N/A
-
-
壓願齋簾廠鏇鏇製顧鹽(襯淵衊製齋簾鑰願壓艱) = 衊製鹹壓獵鹽願製醖廠 餘廠願遞範鑰淵積窪獵 (遞淵蓋築網醖製餘齋壓 )
-
2021-03-01
临床1期
CXCR2 | MMP-9 | TIMP-1
-
(糧艱構窪衊積鹹鑰糧膚) = MGTA-145 monotherapy was well tolerated with no significant adverse events (AEs). Grade 1, transient lower back pain that dissipated within minutes was reported. The combination of MGTA-145 with plerixafor was well tolerated, with some subjects experiencing grade 1/2 gastrointestinal AEs commonly observed with plerixafor and one grade 2 back pain with MGTA-145 at 0.075 mg/kg that resolved within minutes. 積膚繭壓製鏇鹹範鑰餘 (夢餘範夢鏇膚夢構壓齋 )
积极
2020-11-06
临床1期
一线
-
(製窪範廠膚構顧獵衊鹽) = MGTA-145 monotherapy was well tolerated with no significant adverse events (AEs). Grade 1, transient lower back pain that dissipated within minutes was reported. The combination of MGTA-145 with plerixafor was well tolerated, with some subjects experiencing grade 1/2 gastrointestinal AEs commonly observed with plerixafor and one grade 2 back pain with MGTA-145 at 0.075 mg/kg that resolved within minutes. 夢願築鹽網鏇壓繭壓構 (構積鏇襯獵壓選選鑰餘 )
积极
2020-08-29
临床1期
一线
-
(簾糧蓋憲鏇範淵齋鹹網) = some subjects experiencing grade 1/2 gastrointestinal AEs commonly observed with plerixafor and one grade 2 back pain with MGTA-145 at 0.075 mg/kg that resolved within minutes 憲築鹽衊獵襯製憲範蓋 (積齋構衊窪築餘鏇繭觸 )
-
2020-06-03
N/A
-
-
襯製鏇製膚願網憲簾蓋(鏇壓繭淵壓範選範鹽築) = MGTA-145 monotherapy was well tolerated with no significant adverse events (AEs). Grade 1, transient lower back pain that dissipated within minutes was reported. The combination of MGTA-145 with plerixafor was well tolerated, with some subjects experiencing grade 1/2 gastrointestinal AEs commonly observed with plerixafor and one grade 2 back pain with MGTA-145 at 0.075 mg/kg that resolved within minutes. 範顧觸憲構蓋鹽願膚餘 (獵觸壓鑰鏇築鏇鹹鑰艱 )
-
2020-03-01
N/A
-
-
鹹襯膚構繭範夢憲衊壓(餘襯鹹鏇製鑰醖艱糧糧) = 鹽廠網襯糧選廠鑰願鑰 憲廠鏇糧夢壓鏇憲鏇膚 (鹹醖壓衊餘構廠鑰選獵 )
-
2019-03-01
登录后查看更多信息

转化医学

使用我们的转化医学数据加速您的研究。
使用我们的转化医学数据加速您的研究。

药物交易

使用我们的药物交易数据加速您的研究。
使用我们的药物交易数据加速您的研究。

核心专利

使用我们的核心专利数据促进您的研究。
使用我们的核心专利数据促进您的研究。

临床分析

紧跟全球注册中心的最新临床试验。
紧跟全球注册中心的最新临床试验。

批准

利用最新的监管批准信息加速您的研究。
利用最新的监管批准信息加速您的研究。

特殊审评

只需点击几下即可了解关键药物信息。
只需点击几下即可了解关键药物信息。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用